TAT-CF

Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters (TAT-CF)

H2020-PHC-2015-two-stage  (PHC-14-2015)

667079-2      

Roberto Quesada (Department of Organic Chemistry)

Universidad de Burgos (Spain)

• Steinbeis Innovation GmbH (Germany)
• Istituto Giannina Gaslini (Italy)
• Istituto di Biofisica, CNR (Italy)
• Bioneer A/S  (Denmark)
• Biopraxis AEI (Spain)
• Avidin Ktf (Hungary)
• CSIC Consejo Superior de Investigaciones Científicas (Spain)

4,591,228 €

4,591,228 €

665,564 €       

665,564 €       

36 months (01/01/2016-31/12/2018)

rgallo@ubu.es

Cystic fibrosis, regarded as "rare disease" is a chronic hereditary disease with the highest incidence among Caucasians, affecting one in every 5,000 live births. TAT-CF project aims to complete the preclinical development of novel, innovative drugs based on a radically new concept in Cystic Fibrosis therapies: tackling the origin of CF using synthetic small molecules capable of replacing the missing chloride and bicarbonate transmembrane transport activity.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 6677079-2